Literature DB >> 10395286

New molecular and epidemiological issues in mesothelioma: role of SV40.

M Carbone1, S Fisher, A Powers, H I Pass, P Rizzo.   

Abstract

Mesotheliomas are malignant tumors usually associated with occupational asbestos exposure. Simian virus 40 (SV40) is a DNA tumor virus that preferentially causes mesotheliomas when injected intracardially and/or intrapleurally into hamsters. SV40 also transforms human cells in tissue culture, and these cells contain extensive DNA damage. In the United States, at least 60% of human mesotheliomas contain and express SV40. In these tumor cells, the SV40 tumor antigen binds and inhibits the cellular tumor suppressors p53 and Rb. These findings suggest that SV40 may contribute to the development of those human mesotheliomas that occur in people not exposed to asbestos. SV40 may also facilitate asbestos-mediated carcinogenicity. The epidemiological data available are insufficient to address the role that SV40 may have played in contributing to the increased incidence of mesothelioma in the second half of this century.

Entities:  

Mesh:

Year:  1999        PMID: 10395286     DOI: 10.1002/(SICI)1097-4652(199908)180:2<167::AID-JCP4>3.0.CO;2-Q

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  11 in total

1.  Establishment of permanent cell lines purified from human mesothelioma: morphological aspects, new marker expression and karyotypic analysis.

Authors:  Marie-Marthe Philippeaux; Jean-Claude Pache; Sophie Dahoun; Marc Barnet; John-Henri Robert; Jacques Mauël; Anastase Spiliopoulos
Journal:  Histochem Cell Biol       Date:  2004-09-15       Impact factor: 4.304

2.  History of asbestos related disease.

Authors:  P W J Bartrip
Journal:  Postgrad Med J       Date:  2004-02       Impact factor: 2.401

3.  Human mesothelial cells are unusually susceptible to simian virus 40-mediated transformation and asbestos cocarcinogenicity.

Authors:  M Bocchetta; I Di Resta; A Powers; R Fresco; A Tosolini; J R Testa; H I Pass; P Rizzo; M Carbone
Journal:  Proc Natl Acad Sci U S A       Date:  2000-08-29       Impact factor: 11.205

4.  SV40 replication in human mesothelial cells induces HGF/Met receptor activation: a model for viral-related carcinogenesis of human malignant mesothelioma.

Authors:  P Cacciotti; R Libener; P Betta; F Martini; C Porta; A Procopio; L Strizzi; L Penengo; M Tognon; L Mutti; G Gaudino
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-25       Impact factor: 11.205

5.  Fatal hemopericardial tamponade due to primary pericardial mesothelioma: a case report.

Authors:  Daniel C Lingamfelter; Dominick Cavuoti; Amy C Gruszecki
Journal:  Diagn Pathol       Date:  2009-12-09       Impact factor: 2.644

6.  Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma.

Authors:  A Baldi; D Santini; F Vasaturo; M Santini; G Vicidomini; M Pia Di Marino; V Esposito; A M Groeger; G Liuzzi; B Vincenzi; G Tonini; M Piccoli; F Baldi; S Scarpa
Journal:  Thorax       Date:  2004-05       Impact factor: 9.139

7.  p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression.

Authors:  J Creaney; B M McLaren; S Stevenson; A W Musk; N de Klerk; B W Robinson; R A Lake
Journal:  Br J Cancer       Date:  2001-01-05       Impact factor: 7.640

Review 8.  Diagnostic value of microRNAs in asbestos exposure and malignant mesothelioma: systematic review and qualitative meta-analysis.

Authors:  Luigina Micolucci; Most Mauluda Akhtar; Fabiola Olivieri; Maria Rita Rippo; Antonio Domenico Procopio
Journal:  Oncotarget       Date:  2016-09-06

Review 9.  Primary pericardial mesothelioma.

Authors:  Neyyir Tuncay Eren; A Ruchan Akar
Journal:  Curr Treat Options Oncol       Date:  2002-10

Review 10.  Advances in the management of malignant mesothelioma.

Authors:  Mazen Y Khalil; Marissa Mapa; Hyung Ju C Shin; Dong M Shin
Journal:  Curr Oncol Rep       Date:  2003-07       Impact factor: 5.945

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.